The global antibody drug conjugate market was valued at US$ 3,812.3 Million in 2020 and is expected to reach US$ 17,659.7 Million by 2030, growing at a CAGR of 16.4 % from 2021 – 2030.
Antibody Drug Conjugates are highly potent biological drugs designed as a targeted therapy for treating cancerous cells by not harming the healthy cells of the patient. Antibody drug conjugates comprise of three parts- an antibody, an antigen, and a cytotoxic agent which is responsible to kill the targeted cancerous cells sparing the healthy cells. Antibody drug conjugates are considered to be the new age of therapeutic agents as they function by combining the abilities of monoclonal antibodies and cytotoxic drugs as these drugs work only in the targeted cell without giving any damage to nearby cells. The antibody drug conjugate identifies & destroys cancer cells owing to their efficiency and effective mechanism than other cancer treatment methods.
Technological advancements in the medical industry, rising geriatric population, high prevalence of different types of cancer globally, and increased governmental support for the R&D in the pharmaceutical sector are the major reason driving the growth of the global antibody drug conjugate market. The increased urbanization is giving rise to sedentary lifestyles which are further leading to unhealthy habits causing more cancer cells to grow in the body. Antibody drug conjugates are getting immensely popular and the awareness is increasing globally thereby, augmenting the growth of the global antibody drug conjugate market. However, stringent government regulations, delayed reimbursement, and high costs associated with the treatment of cancer are hindering the market growth of the global antibody drug conjugate market.
The global antibody drug conjugate market is bifurcated into Technology, Application, End-Use, and Region. By Technology, the scope of the report offers Cleavable Linker, Non-cleavable Linker, and Linkerless. Among Technology, the Non-cleavable Linker Technology Segment Accounted for Largest Revenue Share owing to its increased plasma stability, higher stability & tolerance level, and greater therapeutic window. By Application, the global market is divided into Blood Cancer, Breast Cancer, Ovarian Cancer, Urothelial Cancer & Bladder Cancer, Lung Cancer, Brain Tumor, and Others. Among all the Cancer, the Blood Cancer segment is anticipated to grow with a moderate CAGR during the forecast period because of growing cases of blood cancer globally. Every 9 minutes, someone in the U.S. dies from blood cancer. New cases of leukemia, lymphoma and myeloma are expected to account for 9.8 percent of the estimated 1,898,160 new cancer cases that will be diagnosed in the U.S. in 2021. The End-Use segment is fragmented into Hospitals & Clinics, Research Institutes, and Others.
Based on Region, the global antibody drug conjugate market is segmented into North America, Europe, Asia-Pacific, and Rest of the World. North America is further classified into the U.S., Canada, and Mexico. Europe is further segmented into Germany, the U.K., France, Italy, Spain, Russia, and the rest of Europe. Asia-Pacific is segmented into China, Japan, India, Australia, South Korea, and the rest of APAC. The RoW includes South & Central America, the Middle East, and Africa. North America is leading the global antibody drug conjugate market because of growing awareness regarding cancer, high prevalence of cancer in the region, and the strong presence of market players in the region.
Prominent market players of the global antibody drug conjugate market are Takeda Pharmaceutical Company Ltd., Pfizer, Inc., GlaxoSmithKline Plc, AstraZeneca, Gilead Sciences, Inc., Sanofi S.A., Daiichi Sankyo Company Ltd., ADC Therapeutics, Seattle Genetics Inc., and Novartis AG, among others.
Market Segmentation and Scope of the Global Antibody Drug Conjugate Market
Rest of the World
Prominent Players of the Global Antibody Drug Conjugate Market